NCT00733135View on ClinicalTrials.gov

Study of the SilverHawk™ /TurboHawk™ Plaque Excision Systems Used With SpiderFX to Treat Calcified Peripheral Arterial Disease (DEFINITIVE Ca++)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Peripheral Arterial Disease
Interventions
DEVICE

SilverHawk™ LS-C, TurboHawk™ LS-C, TurboHawk™ LX-C plaque excision systems and SpiderFX™ embolic protection device

Catheter-based excision of moderate to severely calcified plaque located in the SFA and/or popliteal artery.

Sponsors
All Listed Sponsors
lead

Medtronic Endovascular

INDUSTRY

NCT00733135 - Study of the SilverHawk™ /TurboHawk™ Plaque Excision Systems Used With SpiderFX to Treat Calcified Peripheral Arterial Disease (DEFINITIVE Ca++) | Biotech Hunter | Biotech Hunter